Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2Unknown 1Terminated 1No longer available 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Dermatologic 5Breast 2Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Melanoma 4Uveal Melanoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Rose Bengal × Dermatologic × Clear all
NCT00986661 2022-11-02

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
78 enrolled
BreastDermatologicEndocrineGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Provectus Pharmaceuticals

Phase 3 Terminated
20 enrolled 13 charts
Dermatologic

Melanoma, Recurrence

NCT01260779 2016-07-11

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

Provectus Pharmaceuticals

No longer available
Dermatologic

Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory

NCT00521053 2014-08-25

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

Provectus Pharmaceuticals

Phase 2 Completed
80 enrolled 14 charts
Dermatologic

Melanoma

NCT00219843 2007-08-23

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Provectus Pharmaceuticals

Phase 1 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡